Ace­lyrin files to go pub­lic in rare sign of biotech IPO

Cal­i­for­nia biotech Ace­lyrin has filed to go pub­lic, a rare at­tempt to ac­cess the stock mar­kets af­ter a year of stock de­clines and cut­backs across the in­dus­try.

Ace­lyrin was found­ed by vet­er­ans of Hori­zon Ther­a­peu­tics in 2020, and in-li­cens­es drugs or ac­quires their own­ers, then funds their de­vel­op­ment. The start­up raised a $300 mil­lion Se­ries C last fall, on top of a $250 mil­lion Se­ries B in 2021. It was val­ued at $800 mil­lion af­ter the lat­est round, ac­cord­ing to Pitch­Book.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER